BRIDGEBIO

Aspa's BBP-812 Gene Therapy Program for Canavan Disease: 2026 Updates

Adam Shaywitz, MD, PhD
Chief Medical Officer

May 1st, 2026

NTSAD ANNUAL FAMILY CONFERENCE

Special Thanks to our
Patient Advocacy Organization Partners

For their guidance, collaboration, and unwavering support

NTSAD





Alex THE LEUKODYSTROPHY CHARITY
HELPING TO COPE – HELPING TO HOPE

CANAVAN FOUNDATION
for the Prevention & Cure of Canavan Disease

ELA
EUROPEAN LEUKODYSTROPHIES ASSOCIATION

united LEUKODYSTROPHY FOUNDATION

Fundación Lautaro te necesita
Leucodistrofias

Special Thanks to our Clinical Sites

Massachusetts General Hospital
Founding Member, Mass General Brigham

UCSF Benioff Children's Hospitals

UKE Universitätsklinikum Hamburg-Eppendorf

Ann & Robert H. Lurie Children's Hospital of Chicago®

CANinform

Natural History Study

NTSAD ANNUAL FAMILY CONFERENCE

Courtesy from and proprietary to Aspa Therapeutics, a BridgeBio company

CANinform
Natural History Study

- Enrollment completed
  - Original enrollment goal: **30** participants
  - Final enrollment: **67** participants representing **17** countries

Represents unique countries, not individual participants

NTSAD

- We are deeply **grateful** for the years of support and participation from the community and participant families

- We have gathered **robust and valuable** information about the natural history of Canavan disease which has allowed for **productive regulatory interactions** to take place for our CAN*aspire* gene therapy clinical trial

CANaspire

Gene Therapy Clinical Trial

NTSAD ANNUAL FAMILY CONFERENCE

Courtesy from and proprietary to Aspa Therapeutics, a BridgeBio company

CANaspire
Gene Therapy Clinical Trial

The following slides discuss Aspa's investigational gene therapy BBP-812 which has not been approved by the FDA or other regulatory authorities.

NTSAD

CANaspire
Gene Therapy Clinical Trial

Individual Experience

Study investigators review potential participants for screening on an ongoing basis



Study Overview



NTSAD

CANaspire Gene Therapy Clinical Trial

Enrollment Updates

Dosed Participants		
8 Participants at **Low Dose**	**10** Participants at **High Dose**	**18** Total Participants Dosed
13 International Participants representing 8 countries.	**5** Participants from the United States	

★ Represents unique countries, not individual participants

- Study participation can be burdensome, and Aspa acknowledges and appreciates the continued commitment shown by study participants and their families
- International participants do not pay for travel or accommodations while participating in the CANaspire trial and are supported by a dedicated social worker

NTSAD

CANaspire
Gene Therapy Clinical Trial

Safety Updates

Safety (as of December 2025)
Intravenous (IV) infusions were well-tolerated, with no infusion reactions.
Most adverse events (AEs) were mild or moderate in severity and were considered unlikely or not related to BBP-812.

30 serious adverse events (SAEs) were reported in 16 participants.
• 1 participant passed away; this was deemed unrelated to BBP-812 by investigator and sponsor.
• 1 SAE was considered possibly related to BBP-812.
• 9 SAEs were considered likely related to BBP-812, including:
  • Elevated liver function tests (LFTs)
  • Low platelets (thrombocytopenia) and thrombotic microangiopathy (TMA), involving damage to small blood vessels
  • All serious adverse events thought to be related to BBP-812 have resolved

NTSAD

CANaspire
Gene Therapy Clinical Trial

Multiple measures of possible therapeutic impact are being measured in the study, including Urine-NAA and HINE-2

Urine-NAA



Patients with Canavan disease have a mutation in the ASPA gene that makes it lose function.

This causes a buildup of NAA in the brain and urine.

Urine-NAA can be measured as a marker of ASPA activity.

NTSAD

HINE-2

There are a variety of different methods of measuring "functional" improvements – what patients, families, and physicians can see. One common one is the Hammersmith Infant Neurological Examination part 2 (HINE-2). It's an 8 item scale with the following components:


Head Control


Sitting


Voluntary Grasp


Kicking


Rolling


Crawling


Standing


Walking

CANaspire
Gene Therapy Clinical Trial

Emerging Dose-Dependent Reductions in Urine NAA



- After dosing, urine NAA levels decrease into the range seen in milder Canavan presentation (phenotypes)
- High-dose urine NAA levels are lower than low-dose urine NAA levels.
- Brain (MRS) NAA has been shown to have a correlation with urine NAA both pre and post- treatment

NTSAD

CANaspire
Gene Therapy Clinical Trial

Preliminary Data Show That Children Dosed with BBP-812 Have Improved Motor Function Over Time Compared to Natural History (HINE-2)



- The HINE-2 is a motor function assessment tool used to evaluate motor skills in infants by assessing key developmental milestones
- The test evaluates eight different motor skills: voluntary grasp, head control, kicking, rolling, sitting, crawling, standing, and walking.

NTSAD

As of December 2025

CANaspire
Gene Therapy Clinical Trial

Status of High-Dose Participant 24 Months Post-BBP-812 Dosing

Baseline



Unable to lift head in upright position

Unable to lift head or move in prone

Progress demonstrated on gross motor (head control, sitting) and fine motor (pointing) skills as well as comprehension and understanding

NTSAD

Video used with consent from participant family

CANaspire Gene Therapy Clinical Trial

Status of High-Dose Participant Post-BBP-812 Dosing

Baseline

No head or trunk control in supported sitting

Age at dosing: 10 months

15 months after dosing

Able to sit with UE support with head and trunk control

Stands using furniture for support

18 months after dosing

NTSAD

CANaspire
Gene Therapy Clinical Trial

More Understanding to Come

- Results from the ongoing CAN*aspire* clinical study are encouraging, though they may not be typical for every participant.
- We have had positive engagement with the FDA regarding reduction in urine NAA levels as a potential signal of benefit (surrogate endpoint), use of our Natural History Study data as a comparator, and the maturing clinical data.
- Next Steps: We are continuing to regularly engage with the FDA regarding a potential path to approval for our gene therapy for Canavan.
- More information is needed to fully understand safety and efficacy.

NTSAD

Thank you!

NTSAD ANNUAL FAMILY CONFERENCE

Courtesy from and proprietary to Aspa Therapeutics, a BridgeBio company

CANinform

clinicaltrials.gov/study/NCT04126005

CANaspire

clinicaltrials.gov/study/NCT04998396

Aspa Clinical Studies

treatcanavan.com

Urine NAA Publication

Human Gene Therapy

MAT-US--397

2025 Presentation

NTSAD Family Conference

MAT-US--BBP812-0008 20250418

NTSAD

Hammersmith Infant Neurological Examination — Part 2 (HINE-2)

- The HINE-2 is a motor function assessment tool used to evaluate motor skills in infants by assessing key developmental milestones like head control, sitting, and walking.
- The test evaluates eight different motor skills: voluntary grasp, head control, kicking, rolling, sitting, crawling, standing, and walking.
- The HINE-2 is widely used in clinical trials and research studies to track changes in motor function over time.

MOTOR FUNCTION	MILESTONE PROGRESSION SCORE					
	0	1	2	3	4	Score
Sitting	Cannot sit	With support at hips  *normal at 4m*	Props  *normal at 6m*	Stable sit  *normal at 7-8m*	Pivots (rotates)  *normal at 9m*	